Aclaris Therapeutics Inc. (ACRS)
Aclaris Therapeutics Statistics
Share Statistics
Aclaris Therapeutics has 107.92M shares outstanding. The number of shares has increased by 0.71% in one year.
| Shares Outstanding | 107.92M |
| Shares Change (YoY) | 0.71% |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 91.37M |
| Failed to Deliver (FTD) Shares | 200 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 3.39M, so 3.16% of the outstanding shares have been sold short.
| Short Interest | 3.39M |
| Short % of Shares Out | 3.16% |
| Short % of Float | 3.55% |
| Short Ratio (days to cover) | 3.12 |
Valuation Ratios
The PE ratio is -1.45 and the forward PE ratio is -4.66. Aclaris Therapeutics's PEG ratio is -0.04.
| PE Ratio | -1.45 |
| Forward PE | -4.66 |
| PS Ratio | 10.24 |
| Forward PS | 2.1 |
| PB Ratio | 1.23 |
| P/FCF Ratio | -9.49 |
| PEG Ratio | -0.04 |
Enterprise Valuation
Aclaris Therapeutics Inc. has an Enterprise Value (EV) of 33.85M.
| EV / Earnings | -0.26 |
| EV / Sales | 1.81 |
| EV / EBITDA | -0.65 |
| EV / EBIT | -0.24 |
| EV / FCF | -1.68 |
Financial Position
The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.
| Current Ratio | 3.99 |
| Quick Ratio | 3.99 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.85% and return on capital (ROIC) is -91.24%.
| Return on Equity (ROE) | -0.85% |
| Return on Assets (ROA) | -0.6% |
| Return on Capital (ROIC) | -91.24% |
| Revenue Per Employee | $306,885.25 |
| Profits Per Employee | $-2,165,000 |
| Employee Count | 61 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 39.13% in the last 52 weeks. The beta is 0.5, so Aclaris Therapeutics's price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | 39.13% |
| 50-Day Moving Average | 2.16 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 27.82 |
| Average Volume (20 Days) | 887.26K |
Income Statement
In the last 12 months, Aclaris Therapeutics had revenue of 18.72M and earned -132.06M in profits. Earnings per share was -1.71.
| Revenue | 18.72M |
| Gross Profit | 15.93M |
| Operating Income | -141.93M |
| Net Income | -132.06M |
| EBITDA | -51.72M |
| EBIT | -141.93M |
| Earnings Per Share (EPS) | -1.71 |
Balance Sheet
The company has 24.57M in cash and 0 in debt, giving a net cash position of 24.57M.
| Cash & Cash Equivalents | 24.57M |
| Total Debt | 0 |
| Net Cash | 24.57M |
| Retained Earnings | -902.86M |
| Total Assets | 220.33M |
| Working Capital | 94.36M |
Cash Flow
In the last 12 months, operating cash flow was -20.07M and capital expenditures -121K, giving a free cash flow of -20.2M.
| Operating Cash Flow | -20.07M |
| Capital Expenditures | -121K |
| Free Cash Flow | -20.2M |
| FCF Per Share | -0.26 |
Margins
Gross margin is 85.09%, with operating and profit margins of -758.18% and -705.48%.
| Gross Margin | 85.09% |
| Operating Margin | -758.18% |
| Pretax Margin | -705.48% |
| Profit Margin | -705.48% |
| EBITDA Margin | -276.28% |
| EBIT Margin | -758.18% |
| FCF Margin | -107.88% |
Dividends & Yields
ACRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -106.87% |
| FCF Yield | -11.7% |
Analyst Forecast
The average price target for ACRS is $10.5, which is 556.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.5 |
| Price Target Difference | 556.2% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -4.32 |
| Piotroski F-Score | 1 |